Truist Financial Forecasts Strong Price Appreciation for Pediatrix Medical Group (NYSE:MD) Stock

Key Points

• Truist Financial raised Pediatrix Medical Group’s price target from $28 to $31 while maintaining a “hold” rating, implying 4.43% upside from the prior close.
• Pediatrix reported quarterly EPS of $0.72, beating estimates of $0.65, while revenue of $501.37 million also exceeded forecasts and grew 1.7% year over year.
• Analyst sentiment remains cautious overall: the stock has one Buy rating and five Hold ratings, with an average price target of $27.20, below its reported trading price of $29.68.

Pediatrix Medical Group (NYSE:MD - Get Free Report) had its target price upped by equities researchers at Truist Financial from $28.00 to $31.00 in a research note issued to investors on Friday, Benzinga reports. The firm presently has a "hold" rating on the stock. Truist Financial's target price points to a potential upside of 4.43% from the company's previous close.

MD has been the topic of a number of other reports. Jefferies Financial Group cut Pediatrix Medical Group from a "buy" rating to a "hold" rating and raised their target price for the company from $27.00 to $28.00 in a research note on Wednesday, August 19th. Deutsche Bank Aktiengesellschaft reissued a "hold" rating and set a $25.00 price objective on shares of Pediatrix Medical Group in a research note on Wednesday, August 5th. Weiss Ratings raised shares of Pediatrix Medical Group from a "hold (c+)" rating to a "buy (b-)" rating in a research note on Wednesday, September 9th. Wall Street Zen upgraded shares of Pediatrix Medical Group from a "buy" rating to a "strong-buy" rating in a report on Sunday, September 13th. Finally, UBS Group upped their price objective on shares of Pediatrix Medical Group from $25.00 to $28.00 and gave the stock a "neutral" rating in a report on Thursday, August 6th. One research analyst has rated the stock with a Buy rating and five have issued a Hold rating to the company's stock. Based on data from MarketBeat, Pediatrix Medical Group has an average rating of "Hold" and an average price target of $27.20.

Pediatrix Medical Group Stock Performance

Shares of Pediatrix Medical Group stock traded up $0.50 during trading hours on Friday, hitting $29.68. 269,033 shares of the company were exchanged, compared to its average volume of 782,324. Pediatrix Medical Group has a 1 year low of $16.90 and a 1 year high of $30.55. The company has a current ratio of 1.32, a quick ratio of 1.32 and a debt-to-equity ratio of 0.45. The business has a 50-day moving average of $26.86 and a 200-day moving average of $23.82. The stock has a market capitalization of $2.41 billion, a price-to-earnings ratio of 14.22 and a beta of 0.61.

Pediatrix Medical Group (NYSE:MD - Get Free Report) last released its quarterly earnings results on Thursday, October 29th. The company reported $0.72 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.65 by $0.07. The company had revenue of $501.37 million for the quarter, compared to analysts' expectations of $498.18 million. Pediatrix Medical Group had a net margin of 8.96% and a return on equity of 20.05%. The firm's revenue for the quarter was up 1.7% compared to the same quarter last year. During the same period last year, the company earned $0.67 EPS. As a group, analysts expect that Pediatrix Medical Group will post 2.17 EPS for the current fiscal year.

Hedge Funds Weigh In On Pediatrix Medical Group

Several large investors have recently bought and sold shares of MD. BlackRock Inc. bought a new stake in shares of Pediatrix Medical Group in the 2nd quarter valued at about $347,383,000. Dimensional Fund Advisors LP grew its stake in shares of Pediatrix Medical Group by 8.1% during the first quarter. Dimensional Fund Advisors LP now owns 3,856,915 shares of the company's stock worth $82,496,000 after buying an additional 287,696 shares during the last quarter. Wasatch Advisors LP raised its stake in shares of Pediatrix Medical Group by 21.9% during the second quarter. Wasatch Advisors LP now owns 2,498,884 shares of the company's stock valued at $63,297,000 after acquiring an additional 448,360 shares during the last quarter. Renaissance Technologies LLC lifted its position in shares of Pediatrix Medical Group by 12.9% in the 1st quarter. Renaissance Technologies LLC now owns 1,532,300 shares of the company's stock worth $32,776,000 after purchasing an additional 174,600 shares during the period. Finally, Allspring Global Investments Holdings LLC lifted its stake in Pediatrix Medical Group by 52.5% in the first quarter. Allspring Global Investments Holdings LLC now owns 975,133 shares of the company's stock valued at $20,185,000 after buying an additional 335,733 shares during the period. 97.71% of the stock is currently owned by institutional investors and hedge funds.

Pediatrix Medical Group News Summary

Here are the key news stories impacting Pediatrix Medical Group this week:

• Positive Sentiment: Pediatrix reported quarterly EPS of $0.72, above the consensus estimate of $0.65 and up from $0.67 in the prior-year quarter. Buybacks helped enhance per-share results. Pediatrix Medical Group Q3 2026: Buybacks Drive EPS Beat
• Positive Sentiment: Revenue totaled $501.37 million, beating the $498.18 million analyst forecast and increasing 1.7% year over year. The simultaneous revenue and earnings beats strengthened the market’s response. Pediatrix Medical Group Beats Q3 Earnings and Revenue Estimates
• Positive Sentiment: The company reported an 8.96% net margin and 20.05% return on equity, indicating continued profitability and solid capital efficiency. Pediatrix Medical Group Reports Third-Quarter Results
• Neutral Sentiment: Management discussed the results during the quarterly earnings call, which investors will review for additional details on operating trends, guidance and the outlook for Pediatrix’s physician-services business. Pediatrix Medical Group Q3 2026 Earnings Call Transcript

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc provides specialized physician-led healthcare services for women, infants and children. The company's clinical offerings include neonatal and perinatal care, maternal-fetal medicine, pediatric medical subspecialties, pediatric hospitalist services and related services delivered in partnership with hospitals and healthcare systems.

Pediatrix-affiliated physicians and advanced practice providers generally work in hospital-based settings, including neonatal intensive care units, delivery rooms, pediatric units and outpatient practices.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.